A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours

BACKGROUND: ErbB2 is an attractive target for immunotherapy, as it is a tyrosine kinase receptor overexpressed on tumour cells of different origin, with a key role in the development of malignancy. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer with success, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Borriello, M, Laccetti, P, Terrazzano, G, D'Alessio, G, De Lorenzo, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111160/
https://www.ncbi.nlm.nih.gov/pubmed/21559015
http://dx.doi.org/10.1038/bjc.2011.146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111160/
https://www.ncbi.nlm.nih.gov/pubmed/21559015
http://dx.doi.org/10.1038/bjc.2011.146

Ejemplares similares